gamma-linolenic-acid has been researched along with Diarrhea* in 2 studies
1 trial(s) available for gamma-linolenic-acid and Diarrhea
Article | Year |
---|---|
Self-reported health problems in young male subjects supplementing their diet with oils rich in eicosapentaenoic, gamma-linolenic and stearidonic acids.
Topics: Adult; Diarrhea; Dietary Supplements; Double-Blind Method; Eicosapentaenoic Acid; Fatty Acids, Omega-3; gamma-Linolenic Acid; Humans; Male; Nausea; Oils; Surveys and Questionnaires; Vomiting | 2006 |
1 other study(ies) available for gamma-linolenic-acid and Diarrhea
Article | Year |
---|---|
Chain length of dietary fatty acids determines gastrointestinal motility and visceromotor function in mice in a fatty acid binding protein 4-dependent manner.
We hypothesize that different types of dietary fatty acids (FAs) affect gastrointestinal (GI) motility and visceromotor function and that this effect can be regulated by the fatty acid binding protein 4 (FABP4).. Mice were fed for 60 days with standard diet (STD), STD with 7% (by weight) coconut oil, rich in medium-chain FAs (MCFAs) (COCO), or with 7% evening primrose oil, rich in long-chain FAs (LCFAs) (EPO). In each group, half of the mice received FABP4 inhibitor, BMS309403 (1 mg/kg; i.p.) twice a week. Body weight (BW) and food intake were measured; well-established tests were performed to characterize the changes in GI motility and visceral pain. White adipose tissue and colonic samples were collected for cell culturing and molecular studies.. COCO significantly increased GI transit, but not colonic motility. COCO and EPO delayed the onset of diarrhea, but none affected the effect of loperamide. EPO reduced BW and increased the visceromotor response (VMR) to colorectal distension (CRD). COCO and EPO reduced differentiation of preadipocytes. Treatment with BMS309403: (1) reversed the effects induced by COCO in physiological conditions and in mouse models of diarrhea; (2) prevented the effects of EPO on BW, VMR to CRD and castor oil-induced diarrhea; (3) affected proliferation of preadipocytes; (4) changed the expression of Fabp4 in colonic and adipocyte samples from COCO and EPO.. Modifying dietary intake of MCFAs and LCFAs may be used to control GI motility or visceral pain and thus modulate the symptoms of functional GI disorders. The effect is dependent on the expression of FABP4. Topics: Animals; Coconut Oil; Diarrhea; Diet Therapy; Dietary Fats; Fatty Acid-Binding Proteins; Fatty Acids; gamma-Linolenic Acid; Gastrointestinal Motility; Gastrointestinal Transit; Linoleic Acids; Male; Mice; Mice, Inbred BALB C; Oenothera biennis; Plant Oils; Visceral Pain | 2020 |